Expertise in
28
conditions

Dr. Rupesh R. Kotecha

Radiation Oncology
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 

Overview

Rupesh Kotecha is a Radiation Oncologist practicing medicine in Miami, Florida.

Dr. Kotecha is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Astrocytoma, Glioblastoma, Gamma Knife Radiosurgery, and Vertebroplasty.

He is actively involved in clinical research, co-authoring 259 peer reviewed articles and participating in 10 clinical trials. Dr. Kotecha is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in FL

Hospital Affiliations

Baptist Hospital Of Miami
Mariners Hospital
Doctors Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Baptist Health Miami Cancer Institute
8900 N Kendall Dr, Miami, FL 33176
Other Locations
Baptist Health Cancer Care | Doral
3125 NW 84th Ave, Doral, FL 33122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: May 14, 2026
Intervention Type: Drug
Study Phase: Phase 2
Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery
Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery
Enrollment Status: Recruiting
Publish Date: April 22, 2026
Intervention Type: Drug
Study Drug: 18F fluciclovine
Study Phase: Phase 1
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Temozolomide
Study Phase: Phase 2
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 23, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
Randomized Phase II Study of Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation for Localized Spine Metastasis
Randomized Phase II Study of Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation for Localized Spine Metastasis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
View 8 Less Clinical Trials

259 Total Publications

Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.
Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.
Journal: Journal of neuro-oncology
Published: August 03, 2026
Similar Doctors
Expertise in
13
conditions
Dr. Minesh P. Mehta
Radiation Oncology
Expertise in
13
conditions
Dr. Minesh P. Mehta
Radiation Oncology
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (0.1 miles away)
786-345-7208
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Minesh Mehta is a Radiation Oncologist practicing medicine in Miami, Florida. Dr. Mehta is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Astrocytoma, Glioblastoma, and Vertebroplasty. Dr. Mehta is currently accepting new patients.

Expertise in
32
conditions
Dr. Greg J. Kubicek
Radiation Oncology
Expertise in
32
conditions
Dr. Greg J. Kubicek
Radiation Oncology
Referral may be required
5555 Ponce De Leon Boulevard, 
Coral Gables, FL 
 (4.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Greg Kubicek is a Radiation Oncologist practicing medicine in Coral Gables, Florida. Dr. Kubicek is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Meningioma. Dr. Kubicek is currently accepting new patients.

Expertise in
3
conditions
Dr. Brandon A. Mahal
Radiation Oncology
Expertise in
3
conditions
Dr. Brandon A. Mahal
Radiation Oncology
Referral may be required
5555 Ponce De Leon Boulevard, Floor 1, 
Coral Gables, FL 
 (4.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brandon Mahal is a Radiation Oncologist practicing medicine in Coral Gables, Florida. Dr. Mahal is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Anal Cancer, Breast Cancer, and Prostatectomy. Dr. Mahal is currently accepting new patients.

Frequently Asked Questions about Dr. Rupesh R. Kotecha

How do I make an appointment with Dr. Rupesh R. Kotecha?

You can book an appointment with Dr. Rupesh R. Kotecha by calling their office at 786-345-7208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rupesh R. Kotecha a top-rated expert for Brain Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rupesh R. Kotecha is classified as an Elite expert for Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rupesh R. Kotecha specialize in?

While Dr. Rupesh R. Kotecha is a Radiation Oncology, they have specific expertise in Brain Tumor, Astrocytoma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Rupesh R. Kotecha participate in research or clinical trials?

Yes. Dr. Rupesh R. Kotecha has published 259 articles and abstracts on conditions like Brain Tumor. You can view a list of Dr. Rupesh R. Kotecha's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rupesh R. Kotecha accept my insurance?

Dr. Rupesh R. Kotecha accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 786-345-7208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kotecha's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 11 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile